Towards disease-modifying treatment of Alzheimer's disease: Drugs targeting β-amyloid

Current Alzheimer Research

Volumn 7, Issue 1, 2010, Pages 40-55

  Frisardi, V ^a   Solfrizzi, V ^a   Imbimbo, B P ^b   Capurso, C ^c   D'Introno, A ^a   Colacicco, A M ^a   Vendemiale, G ^c   Seripa, D ^d   Pilotto, A ^d   Capurso, A ^a   Panza, F ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Research and Development Department   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

secretase activators; amyloid; secretase inhibitors; secretase inhibitors; secretase modulators; Active immunotherapy; Alzheimer's disease; Passive immunotherapy

Indexed keywords

ALPHA SECRETASE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AZD 10; BAPINEUZUMAB; BEGACESTAT; BETA SECRETASE INHIBITOR; BMS 708163; BRYOSTATIN 1; CEVIMELINE; CTS 21166; DONEPEZIL; E 2012; EHT 0202; ELND 0005; ELND 005; GALANTAMINE; GAMMA SECRETASE INHIBITOR; HOMOTAURINE; MEMANTINE; MK 0752; MONOCLONAL ANTIBODY; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; PBT 2; PLACEBO; PROTEINASE; QS 21; RIVASTIGMINE; SEMAGACESTAT; TALSACLIDINE; TARENFLURBIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; BIOCHEMISTRY; BRAIN; CLINICAL FEATURE; CLINICAL TRIAL; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; GENETICS; HUMAN; IMMUNOTHERAPY; MILD COGNITIVE IMPAIRMENT; NAUSEA AND VOMITING; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SINGLE DRUG DOSE;

ALZHEIMER DISEASE; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; NEUROPROTECTIVE AGENTS;

EID: 77949768182     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510790274400     Document Type: Review

References (161)

1. Qiu C, De Ronchi D, Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry 20: 380-385 (2007).
2. Panza F, D'Introno A, Colacicco AM, Capurso C, Del Parigi A, Caselli RJ, et al. Current epidemiology of mild cognitive impairment and other predementia syndromes. Am J Geriatr Psychiatry 13: 633-644 (2005).
3. Terry RD. Alzheimer's Disease at mid century (1927-1977), in: Alzheimer: 100 Years and Beyond. (Jucker M, Beyreuther K, Haas C. and Nitsch R, Eds). Springer-Verlag, Berlin Heidelberg, 2006, pp. 58-61.
4. Walter J, Kaether C, Steiner H, Haass C. The cell biology of Alzheimer's disease: uncovering the secrets of secretases. Curr Opin Neurobiol 11: 585-590 (2001).
5. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12: 383-388 (1991).
6. Castellani RJ, Lee HG, Zhu X, Perry G, Smith MA. Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol 67: 523-531 (2008).
7. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 62: 1087-1095 (2003).
8. Francis PT. Glutamatergic approaches to the treatment of cognitive and behavioural symptoms of Alzheimer's disease. Neurodegener Dis 5: 241-243 (2008).
9. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348: 1333-1341 (2003).
10. Hüll M, Berger M, Heneka M. Disease-modifying therapies in Alzheimer's disease: how far have we come? Drugs 66: 2075-2093 (2006).
11. Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 17: 159-165 (2001).
12. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148: 379-397 (2008).
13. Raschetti R, Albanese E, Vanacore N, Maggini M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 4: e338 (2007).
14. Imbimbo BP. The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. Expert Opin Investig Drugs 13: 1469-1481 (2004).
15. Henderson VW. Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience 138: 1031-1039 (2006).
16. Panza F, D'Introno A, Colacicco AM, Capurso C, Pichichero G, Capurso SA, et al. Lipid metabolism in cognitive decline and dementia. Brain Res Rev 51: 275-292 (2006).
17. Salerno-Kennedy R, Cashman KD. Relationship between dementia and nutrition-related factors and disorders: an overview. Int J Vitam Nutr Res 75: 83-95 (2005).
18. Kline EL, McMichael J. Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid protein. WO 91/16819 (1991).
19. Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc Natl Acad Sci USA 93: 452-455 (1996).
20. Schenk D. Prevention and treatment of amyloidogenic disease. WO 99/27944 (1998).
21. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-β attenuates Alzheimer-diseaselike pathology in the PDAPP mouse. Nature 400: 173-177 (1999).
22. Wisniewski T, Konietzko U. Amyloid-β immunisation for Alzheimer's disease. Lancet Neurol 7: 805-811 (2008).
23. Kennedy GJ, Golde TE, Tariot PN, Cummings JL. Amyloid-Based interventions in Alzheimer's disease. CNS Spectr 12(12 suppl 1): 1-14 (2007).
24. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, et al. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7: 369-372 (2001).
25. Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc Natl Acad Sci USA 93: 452-455 (1996).
26. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6: 916-919 (2000).
27. Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE. Amyloid-β immunization eff ectively reduces amyloid deposition in FcRγ-/- knock-out mice. J Neurosci 23: 8532-8538 (2003).
28. Sigurdsson EM, Scholtzova H, Mehta P, Frangione B, Wisniewski T. Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am J Pathol 159: 439-447 (2001).
29. Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-γ derivatives. J Neurosci 24: 6277-6282 (2004).
30. Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative diseass. Annu Rev Neurosci 31: 175-193 (2008).
31. Wisniewski T, Frangione B. Immunological and anti-chaperone therapeutic approaches for Alzheimer's disease. Brain Pathol 15: 72-77 (2005).
32. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, et al. Evaluation of the safety and immunogenicity of synthetic Aγ42 (AN1792) in patients with AD. Neurology 64: 94-101 (2005).
33. Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black RS. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis 5: 194-196 (2008).
34. Wisniewski T. Practice point commentary on Clinical effects of Aγ immunization (AN1792) in patients with AD in an interupted trial. Nat Clin Prac Neurol 1: 84-85 (2005).
35. Robinson SR, Bishop GM, Lee HG, Munch G. Lessons from the AN1792 Alzheimer vaccine: lest we forget. Neurobiol Aging 25: 609-615 (2004).
36. Bombois S, Maurage CA, Gompel M, Deramecourt V, Mackowiak-Cordoliani MA, Black RS, et al. Absence of γ-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch Neurol 64: 583-587 (2007).
37. Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-γ immunization in Alzheimer's disease. Brain Pathol 14: 11-20 (2004).
38. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64: 129-131 (2005).
39. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Müller-Tillmanns B, et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38: 547-554 (2003).
40. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interupted trial. Neurology 64:1553-1562 (2005).
41. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372: 216-223 (2008).
42. Götz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Aβ42 fibrils. Science 293: 1491-1495 (2001).
43. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 62: 1087-1095 (2003).
44. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43: 321-332 (2004).
45. Best JD, Smith DW, Reilly MA, O'Donnell R, Lewis HD, Ellis S, et al. The novel γ secretase inhibitor N-[cis-4-[(4-chlorophenyl) sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque depo-sition without evidence of notch-related pathology in the Tg2576 mouse. J Pharmacol Exp Ther 320: 552-558 (2007).
46. Imbimbo BP, Del Giudice E, Colavito D, D'Arrigo A, Dalle Carbonare M, Villetti G, et al. 1-(3′,4′-Dichloro-2-fluoro[1,1′- biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel γ-secretase modulator, reduces brain β-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp Ther 323: 822-830 (2007).
47. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 22: 721-727 (2001).
48. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging; 30(11): 1728-36 (2009).
49. Singh H, Raghava GP. ProPred: prediction of HLA-DR binding sites. Bioinformatics 17: 1236-1237 (2001).
50. Singh H, Raghava GP. ProPred1: prediction of promiscuous MHC class-I binding sites. Bioinformatics 19: 1009-1014 (2003).
51. Lemere CA, Maron R, Selkoe DJ, Weiner HL. Nasal vaccination with β-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol 20: 705-711 (2001).
52. Zhang J, Wu X, Qin C, Qi J, Ma S, Zhang H, et al. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and β-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol Dis 14: 365-379 (2003).
53. Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, et al. Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48: 567-579 (2000).
54. Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB, et al. Reducing ADlike pathology in 3xTg-AD mouse model by DNA epitope vaccine-a novel immunotherapeutic strategy. PLoS ONE 3:e2124 (2008).
55. Crack PJ, Bray PJ. Toll-like receptors in the brain and their potential roles in neuropathology. Immunol Cell Biol 85: 476-480 (2007).
56. Spinner DS, Kascsak RB, Lafauci G, Meeker HC, Ye X, Flory MJ, et al. CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fi brils. J Leukoc Biol 14: 36-43 (2007).
57. Rosset MB, Ballerini C, Gregoire S, Metharom P, Carnaud C, Aucouturier P. Breaking immune tolerance to the prion protein us ing prion protein peptides plus oligodeoxynucleotide-CpG in mice. J Immunol 172: 5168-5174 (2004).
58. Wyeth E. Wyeth announce encouraging top-line results from phase 2 clinical trial of bapineuzumab for Alzheimer's disease. Available from: http://wyeth.com/news?nav=display&navTo=/wyeth-html/home/news/pressreleases/ 2008/1213683456273.html [accessed: November 30, 2008].
59. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 6: 144-151 (2009).
60. Atwood CS, Bishop GM, Perry G, Smith MA. Amyloid-β: a vascular sealant that protects against hemorrhage? J Neurosci Res 70: 356 (2002)
61. Zhang-Nunes SX, Maat-Schieman ML, Van Duinen SG, Roos RA, Frosch MP, Greenberg SM. The cerebral β-amyloid angiopathies: hereditary and sporadic. Brain Pathol 16: 30-39 (2006).
62. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, et al. Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 298: 1379 (2002).
63. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, et al. Exacerbation of cerebral amyloid angiopathyassociated microhemorrhages in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyoid-β. J Neurosci 25: 629-636 (2005).
64. Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN. Amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 144: 950-960 (2007).
65. Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs DC, et al. Amyloid-β peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 169: 1048-1063 (2006).
66. Vincent B, Cisse MA, Sunyach C, Guillot-Sestier MV, Checler F. Regulation of βAPP and PrPc cleavage by α-secretase: mechanistic and therapeutic perspectives. Curr Alzheimer Res 5: 202-211 (2008).
67. Allinson TM, Parkin ET, Turner AJ, Hooper NM. ADAMs family members as amyloid precursor protein α-secretases. J Neurosci Res 74: 342-352 (2003).
68. Imbimbo BP, Speroni F. β-Amyloid Therapeutic Strategies for Alzheimer's Disease. (Abraham DJ, Ed). Burger's Medicinal Chemistry and Drug Discovery. 6th Edition, John Wiley & Sons Inc, Hoboken, pp. 1-115 (2005).
69. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 113: 1456-1464 (2004).
70. Lopez-Perez E, Zhang Y, Frank SLJ, Creemers J, Seidah N, Checler F. Constitutive α-secretase cleavage of the β-amyloid precursor protein in the furin-deficient LoVo cell line: involvement of the pro-hormone convertase 7 and the disintegrin ADAM10. J Neurochem 76: 1532-1539 (2001).
71. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc Natl Acad Sci USA 98: 5815-5820 (2001).
72. Parvathy S, Ehrlich M, Pedrini S, Diaz N, Refolo L, Buxbaum JD, et al. Atorvastatin-induced activation of Alzheimer's secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding. J Neurochem 90: 1005-1010 (2004).
73. Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME, Gandy S. Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med 2: 69-78 (2005).
74. Famer D, Crisby M. Rosuvastatin reduces caspase-3 activity and up-regulates α-secretase in human neuroblastoma SH-SY5Y cells exposed to A. Neurosci Lett 371: 209-214 (2004).
75. Hoglund K, Thelen KM, Syversen S, Sjogren M, von Bergmann K, Wallin A, et al. The effect of simvastatin treatment on the processing of the amyloid precursor protein in patients with Alzheimer's disease. Neurobiol Aging 25: S584 (abstract P4-386) (2004).
76. Kozikowski AP, Nowak I, Petukhov PA, Etcheberrigaray R, Mohamed A, Tan M, et al. New amide-bearing benzolactam-based protein kinase C modulators induce enhanced secretion of the amyloid precursor protein metabolite sAPPα. J Med Chem 46: 364-373 (2003).
77. Etcheberrigaray R, Tan M, Dewachter I, Kuipéri C, Van der Auwera I, Wera S, et al. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci USA 101: 11141-11146 (2004).
78. National Institute on Aging. Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease [on-line]. Available from URL: http://www.clinicaltrials.gov [Accessed 30 November 2008].
79. Hock C, Maddalena A, Heuser I, Naber D, Oertel W, von der Kammer H, et al. Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid β-peptide in patients with Alzheimer's disease. Ann NY Acad Sci 920: 285-291 (2000).
80. Hock C, Maddalena A, Raschig A, Müller-Spahn F, Eschweiler G, Hager K, et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42 in patients with Alzheimer's disease. Amyloid 10: 1-6 (2003).
81. Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH. The selective muscarinic M1 agonist AF102B decreases levels of total Aβ in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 48: 913-918 (2000).
82. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, et al. M1 receptors play a central role in modulating AD like pathology in transgenic mice. Neuron 49: 671-682 (2006).
83. Obregon DF, Rezai-Zadeh K, Bai Y, Sun N, Hou H, Ehrhart J, et al. ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate- induced α-secretase cleavage of amyloid precursor protein. J Biol Chem 281: 16419-16427 (2006).
84. Marcello E, Gardoni F, Mauceri D, Romorini S, Jeromin A, Epis R, et al. Synapse-associated protein-97 mediates α-secretase ADAM10 trafficking and promotes its activity. J Neurosci 14: 1682-1691 (2007).
85. Desire L, Drouin D, Sol O, Lambeng N, Schweighoffer F. EHT 0202: a neuroprotective and procognitive α-secretase stimulator targeted towards Alzheimer's disease therapy. Eur J Neurol 15: (Suppl. 3): 1104 (Abstract P1019) (2008).
86. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. α-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735-741 (1999).
87. Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J. Human aspartic protease memapsin 2 cleaves the α-secretase site of β-amyloid precursor protein. Proc Natl Acad Sci USA 97: 1456-1460 (2000).
88. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, et al. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain:implications for Alzheimer's disease therapeutics. Hum Mol Genet 10: 1317-1324 (2001).
89. Hook VY, Kindy M, Hook G. Inhibitors of cathepsin B improve memory and reduce β-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, β-secretase site of the amyloid precursor protein. J Biol Chem 283: 7745-7753 (2008).
90. Gruninger-Leitch F, Schlatter D, Kung E, Nelbock P, Dobeli H. Substrate and inhibitor profile of BACE (β-secretase) and comparison with other mammalian aspartic proteases. J Biol Chem 277: 4687-4693 (2002).
91. Ghosh AK, Kumaragurubaran N, Hong L, Koelsh G, Tang J. Memapsin 2 (β-secretase) inhibitors: drug development. Curr Alzheimer Res 5: 121-131 (2008).
92. Ghosh AK, Shin DW, Downs D, Koelsch G, Lin XL, Ermolieff J, et al. Design of potent inhibitors for human brain memapsin 2 (β-Secretase). J Am Chem Soc 122: 3522-3523 (2000).
93. Ghosh AK, Bilcer G, Harwood C, Kawahama R, Shin D, Hussain KA, et al. Structure-based design: potent inhibitors of human brain memapsin 2 (β-secretase). J Med Chem 44: 2865-2868 (2001).
94. Asai M, Hattori C, Iwata N, Saido TC, Sasagawa N, Szabó B, et al. The novel β-secretase inhibitor KMI-429 reduces amyloid β peptide production in amyloid precursor protein transgenic and wildtype mice. Neurochem 96: 533-540 (2006).
95. Park ICH, Jeon SY, Lee HJ, Kim SI, Song KS. A β-secretase (BACE1) inhibitor hispidin from the mycelial cultures of Phellinus linteus. Planta Med 70: 143-146 (2004).
96. Jeon SY, Bae K, Seong YH, Song KS. Green tea catechins as a BACE1 (β-secretase) inhibitor. Bioorg Med Chem Lett 13: 3905-3908 (2003).
97. Ghosh AK, Devasamudram T, Hong L, DeZutter C, Xu X, Weerasena V, et al. Structure-based design of cycloamideurethane-derived novel inhibitors of human brain memapsin 2 (β-secretase). Bioorg Med Chem Lett 15: 15-20 (2005).
98. Turner RT 3rd, Hong L, Koelsch G, Ghosh AK, Tang J. Structural locations and functional roles of new subsites S(5), S(6), and S(7) in memapsin 2 (β-secretase). Biochemistry 44: 105-112 (2005).
99. Chang WP, Koelsch G, Wong S, Downs D, Da H, Weerasena V, et al. In vivo inhibition of Aβ production by memapsin 2 (β-secretase) inhibitors. J Neurochem 89: 1409-1416 (2004).
100. Chang WP, Downs D, Huang XP, Da H, Fung KM, Tang J. Amyloid-β reduction by memapsin 2 (β-secretase) immunization. FASEB J 21: 3184-3196 (2007).
101. He X, Cooley K, Chung CH, Dashti N, Tang J. Apolipoprotein receptor 2 and X11 α/β mediate apolipoprotein E-induced endocytosis of amyloid-β precursor protein and β-secretase, leading to amyloid-β production. J Neurosci 27: 4052- 4060 (2007).
102. Ghosh AK, Kumaragurubaran N, Hong L, Kulkarni S, Xu X, Miller HB, et al. Potent memapsin 2 (β-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation. Bioorg Med Chem Lett 18: 1031-1036 (2008).
103. CoMentis Announces Proof-of-Activity-Data from its Phase I Study of Disease-Modifying Alzheimer's Disease Therapy CoMentis News Room. Available from URL: www.athenagen.com/index.php?/athenagen/press-releases/48 [Accessed 30 November 2008].
104. CoMentis receives FDA clearance to begin human clinical trials for its disease-modifying Alzheimer's therapy. CoMentis News Room. Available from URL: www.athenagen.com/index.php?/athenagen/press-releases/45 [Accessed 30 November 2008].
105. Armogida M, Petit A, Vincent B, Scarzello S, Alves da Costa C, et al. Endogenous β-amyloid production in presenilin deficient embryonic mouse fibroblasts. Nature Cell Biol 3: 1030-1033 (2001).
106. Lai MT, Crouthamel MC, DiMuzio J, Pietrak BL, Donoviel DB, Bernstein A, et al. A presenilin-independent aspartyl protease prefers the γ-42 site cleavage. J Neurochem 96: 118-125 (2006).
107. Imbimbo BP. Therapeutic potential of γ-secretase inhibitors and modulators. Curr Top Med Chem 8: 54-61 (2008).
108. Imbimbo BP. Alzheimer's Disease: γ-Secretase Inhibitors. Drug Discov Today Ther Strateg 5(3): 169-75 2008 (in press).
109. Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ. Skeletal and CNS defects in presenilin-1-deficient mice. Cell 89: 629-639 (1997).
110. Lewis HD, Perez Revuelta BI, Nadin A, Neduvelil JG, Harrison T, Pollack SJ, et al. Catalytic site-directed γ-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and β-APP cleavages. Biochemistry 42: 7580-7586 (2003).
111. Maillard I, Adler SH, Pear WS. Notch and the immune system. Immunity 19: 781-791 (2003).
112. Stanger BZ, Datar R. Murtaugh LC, Melton DA. Direct regulation of intestinal fate by Notch. Proc Natl Acad Sci USA 102: 12443-12448 (2005).
113. Schouwey K, Beermann F. The Notch pathway: hair graying and pigment cell homeostasis. Histol Histopathol 23: 609-619 (2008).
114. Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR, et al. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional γ-secretase inhibitor. J Biol Chem 278: 46107-46116 (2003).
115. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, et al. Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain. J Neurochem 76: 173-181 (2001).
116. Rosen LB, Stone JA, Plump A, Yuan J, Harrison T, Flynn M, et al. The γ secretase inhibitor MK-0752 acutely and significantly reduces CSF Aβ40 concentrations in humans. Alzheimers Dement 2 (Suppl. 1): S79 (Abstract O4-03-02) (2006).
117. Albright CF, Dockens R, Olson RE, Meredith J, Slemmon R, Lentz K, et al. BMS-708163, a potent and selective γ-secretase inhibitor, decreases CSF Aβ at safe and tolerable doses in animals and humans. International Conference on Alzheimer's Disease, 26-31 July, Chicago, IL, USA (Abstract HT-01-05) (2008).
118. Wood KM, Lanz TA, Coffman KJ, Becker SL, van Deusen J, Nolan CE, et al. Efficacy of the novel γ-secretase inhibitor, Pf-3084014, in reducing Aβ in brain, CSF, and plasma in guinea pigs and Tg2576 mice. Alzheimers Dement (4 Suppl. 2): T482 (Abstract P2-375) (2008).
119. Frick G, Raje S, Wan H, Forlow SB, Balliet C, Pastore A, et al. GSI-953, a potent and selective γ-secretase inhibitor-modulation of β amyloid peptides and plasma and cerebrospinal fluid pharmacokinetic/ pharmacodynamic relationships in humans. Alzheimers Dement 4 (Suppl. 2): T781 (Abstract P4-366) (2008).
120. Ness DK, Boggs LN, Hepburn DL, Gitter B, Long GG, May PC, et al. Reduced β-amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months. Neurobiol Aging 25 (Suppl. 2): 238 (2004).
121. Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, et al. Safety, tolerability, and changes in amyloid β concentrations after administration of a γ-secretase inhibitor in volunteers. Clin Neuropharmacol 28: 126-132 (2005).
122. Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, et al. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-β after inhibition of γ-secretase. Clin Neuropharmacol 30: 317-325 (2007).
123. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, et al. Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66: 602-604 (2006).
124. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, et al. Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease. Arch Neurol 65: 1031-1038 (2008).
125. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, et al. A γ-secretase inhibitor decreases amyloid-β production in the central nervous system. Ann Neurol 66(1): 48-54 (2009).
126. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414: 212-216 (2001).
127. Wolfe MS. Inhibition and modulation of γ-secretase for Alzheimer's disease. Neurotherapeutics 5: 391-398 (2008).
128. Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, et al. Substrate-targeting γ-secretase modulators. Nature 453: 925-929 (2008).
129. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ 42 in vivo. J Clin Invest 112: 440-449 (2003).
130. Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy MP, Koo EH, et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci 8: 54 (2007).
131. Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, et al. Safety, tolerability, pharmacokinetics and Aβ levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord 21: 292-299 (2007).
132. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA. Tarenflurbil Phase II Study investigators. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease; a randomised phase II trial. Lancet Neurol 7: 483-493 (2008).
133. Available from URL: http://www.alzforum.org [Accessed 30 November 2008].
134. Imbimbo BP. Why did Flurizan fail? J Alzheimers Dis (2009) (In press).
135. Lanz TA, Fici GJ, Merchant KM. Lack of specific amyloid-β1-42 suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J Pharmacol Exp Ther 312: 399-406 (2005).
136. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 54: 588-593 (2000).
137. Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30: 1204-1215 (2005).
138. ADAPT Research Group, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68: 1800-1808 (2007).
139. Wagner S, Kounnas M, Tyree C, Cheng S, Danks A, Ackermann L, et al. Modulators of γ-secretase activity that lower Aβ42 levels without affecting Notch proteolytic processing. 7th International Conference AD/PD, Sorrento, Italy, March 9-13. Abstract Book. p. 11 (2005).
140. Beher D, Bettati M, Checksfield GD, Churcher I, Doughty VA, Oakley PJ, et al. Treatment of Alzheimer's disease and related conditions. WO 2005/013985 A1, (2005).
141. Kimura T, Kawano K, Doi E, Kitazawa N, Shin K, Miyagawa T, et al. Ciannamide compound. US 2006/0004013 A1, (2006).
142. Geerts H. NC-531 (Neurochem). Curr Opin Investig Drugs 5: 95-100 (2004).
143. Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, et al. Targeting soluble Aβ peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 28: 537-547 (2007).
144. Aisen PS, Gauthier S, Vellas B, Briand R, Saumier D, Laurin J, et al. A Phase II study targeting amyloid-β with 3APS in mild-tomoderate Alzheimer disease. Neurology 67: 1757-1763 (2006).
145. Available from URL: http://www.alzforum.org/new/detail. asp?id=1647 [Accessed 30 November 2008].
146. Bush AI. Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimers Dis 15: 223-240 (2008).
147. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, et al. Treatment with a copperzinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30: 665-676 (2001).
148. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60: 1685-1691 (2003).
149. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 8: 779-786 (2008).
150. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ. Neuron 59: 43-55 (2008).
151. McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid β peptide and inhibit aβ-induced toxicity. J Biol Chem 275: 18495-18502 (2000).
152. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, et al. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12: 801-808 (2006).
153. National Institute on Aging. ELND005 in Patients With Mild to Moderate Alzheimer's Disease [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 30 November 2008].
154. Estrada LD, Soto C. Disrupting β-amyloid aggregation for Alzheimer disease treatment. Curr Top Med Chem 7: 115-126 (2007).
155. Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W, et al. Lipids revert inert Aβ amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J 27: 224-233 (2008).
156. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 1403 (1976).
157. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A
158. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 7: 293-303 (1996).
159. Castellani RJ, Lee HG, Zhu X, Nunomura A, Perry G, Smith MA. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol 111: 503-509 (2006).
160. Lee HG, Zhu X, Nunomura A, Perry G, Smith MA. Amyloid β: the alternate hypothesis. Curr Alzheimer Res 3: 75-80 (2006).
161. Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, et al. Redox-active iron mediates amyloid-β toxicity. Free Radic Biol Med FEB 30: 447-450 (2001).